Correlation Between Ascletis Pharma and Salarius Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Ascletis Pharma and Salarius Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ascletis Pharma and Salarius Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ascletis Pharma and Salarius Pharmaceuticals, you can compare the effects of market volatilities on Ascletis Pharma and Salarius Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ascletis Pharma with a short position of Salarius Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ascletis Pharma and Salarius Pharmaceuticals.

Diversification Opportunities for Ascletis Pharma and Salarius Pharmaceuticals

-0.35
  Correlation Coefficient

Very good diversification

The 3 months correlation between Ascletis and Salarius is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Ascletis Pharma and Salarius Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Salarius Pharmaceuticals and Ascletis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ascletis Pharma are associated (or correlated) with Salarius Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Salarius Pharmaceuticals has no effect on the direction of Ascletis Pharma i.e., Ascletis Pharma and Salarius Pharmaceuticals go up and down completely randomly.

Pair Corralation between Ascletis Pharma and Salarius Pharmaceuticals

Assuming the 90 days horizon Ascletis Pharma is expected to generate 0.68 times more return on investment than Salarius Pharmaceuticals. However, Ascletis Pharma is 1.46 times less risky than Salarius Pharmaceuticals. It trades about 0.09 of its potential returns per unit of risk. Salarius Pharmaceuticals is currently generating about 0.01 per unit of risk. If you would invest  15.00  in Ascletis Pharma on September 3, 2024 and sell it today you would earn a total of  3.00  from holding Ascletis Pharma or generate 20.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy98.46%
ValuesDaily Returns

Ascletis Pharma  vs.  Salarius Pharmaceuticals

 Performance 
       Timeline  
Ascletis Pharma 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Ascletis Pharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile essential indicators, Ascletis Pharma reported solid returns over the last few months and may actually be approaching a breakup point.
Salarius Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Salarius Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Salarius Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Ascletis Pharma and Salarius Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Ascletis Pharma and Salarius Pharmaceuticals

The main advantage of trading using opposite Ascletis Pharma and Salarius Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ascletis Pharma position performs unexpectedly, Salarius Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Salarius Pharmaceuticals will offset losses from the drop in Salarius Pharmaceuticals' long position.
The idea behind Ascletis Pharma and Salarius Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
CEOs Directory
Screen CEOs from public companies around the world